Related Experiment Video
Updated: Aug 22, 2025
An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
Published on: July 28, 2012
Long Non-Coding RNA and Chemoresistance in Bladder Cancer - A Mini Review
Ana Paula Braga Lima1, Glenda Nicioli da Silva1,2,3
1Programa de Pós-graduação em Ciências Farmacêuticas (CIPHARMA), Universidade Federal de Ouro Preto, Ouro Preto, Minas Gerais, Brazil.
Abstract:
Bladder cancer is the 10th most common cancer worldwide. It is a heterogeneous disease, comprising several tumor subtypes with differences in histology, genomic aberrations, prognosis and sensitivity to anti-cancer treatments. Although the treatment of bladder cancer is based tumor classifications and gradings, patients have different clinical response. In recent years, long non-coding RNAs (lncRNAs) were associated with bladder cancer chemoresistance. Thus, lncRNAs seem to be promising targets in treatment of bladder cancer. This review highlights the recent findings concerning lncRNAs and their relevance to the chemoresistance of bladder cancer. This may provide a basis for exploiting more robust therapeutic approaches in the future.
Insights
Long non-coding RNAs (lncRNAs) are linked to bladder cancer chemoresistance. Understanding lncRNAs offers potential for developing new bladder cancer treatments.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Bladder cancer is a common, heterogeneous disease with variable treatment responses.
- Current treatments rely on tumor classification and grading, but clinical outcomes differ.
- Long non-coding RNAs (lncRNAs) have emerged as key players in cancer development and progression.
Approach:
- This review synthesizes recent research on lncRNAs in bladder cancer.
- It focuses specifically on the role of lncRNAs in chemoresistance.
- The review aims to consolidate current knowledge for future therapeutic development.
Key Points:
- Bladder cancer exhibits significant heterogeneity, impacting treatment efficacy.
- lncRNAs are increasingly recognized for their involvement in chemoresistance across various cancers.
- Specific lncRNAs have been identified as potential modulators of bladder cancer cell sensitivity to chemotherapy.
Conclusions:
- lncRNAs represent promising therapeutic targets for overcoming bladder cancer chemoresistance.
- Further research into lncRNA functions can guide the development of novel treatment strategies.
- Exploiting lncRNA pathways may lead to more effective and personalized bladder cancer therapies.
Related Concept Videos
02:39lncRNA - Long Non-coding RNAs
02:56Treatment Resistant Cancers
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...